Paracetamol in pregnancy and alleged autism: Trump announces restrictions, but Swedish studies dismiss link

Trump announced at the White House a measure shaking the debate on gestational health in the United States. Alongside Health Secretary Robert F. Kennedy Jr., the president linked the use of paracetamol, known as Tylenol in the U.S., to a supposed rise in autism spectrum disorder cases in children. The statement came during a press conference promising medical advancements but drew immediate criticism from entities like the World Health Organization and the European Medicines Agency.

The measure directs the Food and Drug Administration to notify doctors to limit the drug in pregnant women, except in essential cases. Trump argued that the analgesic contributes to what he called a meteoric rise in autism diagnoses, citing study reviews suggesting associations. However, Kenvue, the manufacturer of Tylenol, promptly rebutted, stating that independent data do not support such a connection.

Neurodevelopment experts emphasize that paracetamol remains a safe option for pain and fever during pregnancy, especially compared to alternatives like ibuprofen, which carry documented fetal risks.

• Trump’s announcement occurred on September 22, 2025, during an official White House event.
• Kennedy Jr., known for questioning vaccines, reinforced the narrative of an environmental ‘epidemic.’
• Kenvue saw its shares dip initially but recover part of the value the next day.
• Autism advocacy groups issued statements of repudiation, calling the remarks stereotyped.

The focus on leucovorin as a potential therapy for autistic symptoms also marked the announcement. The government plans to expand access to the drug via Medicaid, based on preliminary trials suggesting improvements in verbal communication.

Position of international entities on paracetamol

The European Commission issued a statement reaffirming the lack of evidence linking paracetamol to autism. Representatives emphasized that the drug can be used when necessary, prioritizing minimal doses and short duration under professional guidance. This stance aligns with established guidelines considering it the primary choice for pregnant women, avoiding complications from untreated fever, which itself affects fetal development.

In the United Kingdom, the National Health Service maintained its unchanged recommendation, describing the analgesic as widely used during pregnancy without harm to the baby. British authorities noted that unfounded warnings may discourage appropriate use, raising unnecessary risks for mothers and children.

The World Health Organization, in turn, classified the evidence as inconsistent during a Geneva briefing. Spokesperson Tarik Jašarević explained that, while observational studies suggest correlations, more robust analyses eliminate confounding factors, such as underlying infections prompting the drug’s use.

These international responses contrast with the urgency of the U.S. government, which plans an educational campaign and adjustments to generic paracetamol labeling. Critics argue such initiatives may spark disproportionate panic among pregnant women, especially in contexts with limited access to medical care.

Understanding autism spectrum disorder

Autism spectrum disorder manifests in varied ways, ranging from mild challenges in social interactions to needs for intensive support. It stems from differences in early brain development, primarily influenced by genetic factors accounting for 85% to 90% of cases, according to large-scale research.

Diagnoses encompass language delays, repetitive behavior patterns, and sensory sensitivities, but the spectrum allows individuals to lead fulfilling lives with appropriate accommodations. Advances in early screening facilitate interventions that enhance social and cognitive skills over time.

Genetic studies identify mutations in hundreds of genes associated with ASD, with common familial inheritance even in parents without evident symptoms. Environmental factors, such as prenatal exposures, interact with this genetic base, but isolating them as sole causes remains challenging.

• Early identification ideally occurs before age two, via observation of developmental milestones.
• ASD affects about 1 in 36 children in the U.S., with similar rates in other developed countries.
• Girls often present subtler symptoms, leading to historical underdiagnosis.
• Educational and therapeutic support has evolved, including inclusive programs in public schools.
• Current research explores biomarkers for more precise and personalized diagnoses.

Evolution of diagnostic criteria and prevalence rates

Changes in diagnostic manuals, like the DSM-5 adopted in 2013, broadened criteria to include milder forms of ASD, incorporating what was previously classified as pervasive developmental disorder. This expansion led to increased detection, driven by public awareness and incentives for evaluations in educational settings.

In the United States, the Centers for Disease Control and Prevention recorded a rate of 1 in 150 children in 2000, jumping to 1 in 36 by 2020. Experts attribute this to improved screening, not necessarily a true rise in population incidence.

Guilherme Polanczyk, a psychiatrist at the University of São Paulo, notes that current criteria capture subtle difficulties overlooked in the past, facilitating access to services unavailable decades ago. This dynamic explains the growth without implying exclusive environmental epidemics.

In developing countries, similar rates emerge with investments in child mental health, suggesting access barriers, not biological variations, shape global statistics.

Polanczyk stresses the distinction between diagnoses and true prevalence, cautioning against alarmist narratives that stigmatize neurodivergent conditions.

Analysis of key studies on paracetamol and neurodevelopment

A Swedish study published in JAMA in 2024 examined data from 2.5 million children, finding minimal initial associations between prenatal paracetamol exposure and risks of autism or ADHD. When adjusted for confounders like maternal infections, the links vanished, especially in comparisons among siblings from the same family.

Researchers highlighted that the sibling design minimizes shared genetic and environmental biases, strengthening the conclusion of no causality. The absolute differences observed were negligible, such as a 0.09% increase in ASD diagnoses at age 10.

An August 2025 review in Environmental Health, conducted by Harvard experts, analyzed 46 observational studies. Of the 27 indicating positive associations, many faced limitations in exposure measurement, opting not to quantify unique risks due to inconsistencies.

The authors recommended cautious use of the drug but reiterated its status as the preferred analgesic in pregnancy, prioritizing medical guidance for low and brief doses.

Smaller studies, like a 2016 Spanish one in the International Journal of Epidemiology, reported associations in boys for autistic symptoms, but samples limited to 2,644 mother-child pairs prevent generalizations.

• The Swedish study used national registries for precision in exposures and outcomes.
• The Harvard review emphasized methodological quality, with robust studies less likely to show associations.
• Common confounders include maternal fever, which independently raises neurodevelopmental risks.
• ‘Frequent’ gestational doses correlated to odds ratios of 1.2 for ASD in meta-analyses.
• Future longitudinal research plans to monitor long-term cohorts for validation.

Leucovorin as an emerging therapeutic option

Leucovorin, an active form of folic acid, gained attention in small clinical trials for relieving autistic symptoms, particularly in communication and irritability. A SUNY Downstate Medical Center study tested the compound in children with cerebral folate transport barriers, noting verbal gains in up to 75% of participants.

The Food and Drug Administration approved a GSK version in 2025, citing reviews in rare folate deficiencies mimicking autistic traits. However, the Autism Science Foundation warns that evidence stems from four randomized trials with varied doses and heterogeneous outcomes.

Richard Frye, a pediatric neurologist, describes the research as preliminary, needing larger trials to confirm efficacy in specific genetic subgroups. The Trump administration plans Medicaid coverage, but experts urge caution against premature expectations.

Studies suggest genetic variations affect folate processing in three-quarters of autistic children, potentially enhancing leucovorin’s benefits over standard folic acid supplements.

Researchers explore critical developmental windows where early interventions maximize impacts, but ASD’s heterogeneity complicates uniform drug responses.

Reactions from the autistic community and risks of misinformation

Arthur Ataide Garcia, vice-president of Autistas Brasil, criticized Trump’s statements as fuel for political crusades detached from science. He argued that reducing autistics to dependency stereotypes ignores valuable contributions and perpetuates exclusion.

A 2025 regional mapping identified Brazil as a leader in disseminating false ASD causes, with spikes on digital platforms. Garcia advocated for investments in educational inclusion and emancipation, rather than searches for miraculous cures.

In the U.S., dozens of medical groups, including the American Academy of Pediatrics, condemned the announcement as irresponsible, predicting confusion among pregnant women and delays in essential fever treatments.

The Autism Science Coalition emphasized that baseless narratives fuel unwarranted fears, diverting resources from rigorous genetic and behavioral research.

Experts like Polanczyk reinforce that ASD demands holistic approaches, focusing on individualized support that respects inherent neurodiversity.

• Investments in inclusive policies grew 20% in recent years in OECD nations.
• Misinformation about ‘cures’ affects 40% of families in Latin American surveys.
• Autistic groups lead campaigns for representation in clinical studies.
• Evidence-based therapies, like modified ABA, show gains in 70% of early cases.
• International collaborations aim to standardize screenings for global equity.

Implications for pregnant women and practical guidance

Pregnant women face dilemmas balancing symptom relief with emerging concerns, but medical consensus maintains paracetamol as a therapeutic cornerstone. Universal recommendations include prior consultation for personalized dosing, avoiding prolonged self-medication.

Fever above 38.5°C in pregnancy demands swift intervention, as fetal hyperthermia is linked to malformations independent of drugs. Non-pharmacological alternatives, like cold compresses, complement the arsenal.

In Brazil, the Federal Council of Medicine aligns with global guidelines, promoting education on rational use in prenatal campaigns. Pharmacists play a key role in informed dispensing.

Ongoing research monitors multiple exposures, integrating longitudinal cohort data to clarify subtle environmental interactions.

Mothers with a family history of ASD benefit from genetic counseling, which contextualizes risks without alarmism.